ALS Studies and Lessons Learned From COVID-19


Michael Murphy, MD, PhD | Barry Dussault | Tom Babic, MD, PhD | Stephen Kirzinger | Chris Mason | Steohen Kirzinger | Natalie Richard | Jeanine Ronniger | Konstantin Schupachenko | Lucie Undus

The disruptions caused by COVID-19 have complicated both the initiation and execution of clinical trials involving therapies targeting amyotrophic lateral sclerosis (ALS). Read our experts’ perspectives on how to flex during this global pandemic.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Michael Murphy, MD, PhD
MEET THE AUTHOR

Michael Murphy, MD, PhD

Chief Medical and Scientific Officer
LEARN MORE
Barry Dussault
MEET THE AUTHOR

Barry Dussault

Executive Director, Project Management, Franchise Area Lead, Analgesia, Addiction, and Neurology Rare Disorders
LEARN MORE
Tom Babic, MD, PhD
MEET THE AUTHOR

Tom Babic, MD, PhD

Vice President, Scientific Solutions, Neuroscience
LEARN MORE